Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?

• Главные авторы: M. Rossini (Автор), O Viapiana (Автор), G. Orsolini (Автор), E. Fracassi (Автор), L. Idolazzi (Автор), D. Gatti (Автор), S. Adami (Автор), M. Govoni (Автор)
• Формат: ‌
• Опубликовано: PAGEPress Publications, 2015-03-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic...